No Data
Oppenheimer Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Raises Target Price to $12
Laidlaw Initiates Aldeyra Therapeutics(ALDX.US) With Buy Rating, Announces Target Price $11
Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment
Express News | Aldeyra Therapeutics Inc - FDA Review of Nda Resubmission Expected Within 6 Months
Express News | Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Express News | Aldeyra Therapeutics: Amendment Extends Expiration to April 1, 2026